Press release, Helsinki, 10 July 2025 at 9 AM (EEST) 

Distributor Orders Nexstim NBS 6 System

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received order for an NBS 6 system from a distributor. The end customer is a Nordic therapy clinic that is acquiring their first Nexstim system.

The NBS (Navigated Brain Stimulation) 6 is a new generation Nexstim system. Developed in collaboration with Nexstim’s customers, the NBS 6 system makes the Company’s clinically established, e-field navigated TMS (transcranial magnetic stimulation) technology more user-friendly than ever before.  The NBS 6 system is currently CE-marked for the treatment of major depression and chronic neuropathic pain in the EU, and FDA-cleared for the treatment of major depressive disorder in the United States.

Mikko Karvinen, CEO of Nexstim, comments: “This new customer will use our system to treat both chronic neuropathic pain and major depression.

A syndrome of chronic neuropathic pain may develop after damage to nerves, due to accident, disease or even an amputation. Targeting rTMS, repetitive TMS, to the motor cortex, or related areas, has resulted in meaningful relief for some patients.

Nexstim NBS 6 for depression is intended to be used in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Both our experienced and new customers have been excited about the new software, and many have already treated a great number of patients with the NBS 6.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com

AttachmentsNexstim Plc_Press release_Eur order_10072025_FINAL.pdf